/ Not yet recruiting临床1/2期 A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
100 项与 RPTR-1-201 相关的临床结果
100 项与 RPTR-1-201 相关的转化医学
100 项与 RPTR-1-201 相关的专利(医药)
100 项与 RPTR-1-201 相关的药物交易